Alphatec CEO Miles Patrick Purchases 115,000 Shares for $1 Million. Is the Medical Tech Stock Now a Buy?
Key Points
The purchase of ~115,000 shares at a weighted average price of $8.81 per share represents a total capital commitment of $1.0 million.
The transaction involved shares equal to 2% of the stake held by the executive before the filing.
This open-market activity increased the CEO's total beneficial ownership to ~6.2 million shares following a -42% one-year total return for the stock as of September 10, 2026.
- 10 stocks we like better than Alphatec ›
Miles Patrick, the Chairman and CEO of Alphatec Holdings, Inc. (NASDAQ:ATEC), purchased ~115,000 shares of common stock on September 10, 2026, according to an SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | $1.0 million |
| Shares purchased (directly held) | ~115,000 |
| Post-transaction shares (directly held) | ~5.9 million |
| Post-transaction shares (indirectly held) | ~260,900 |
| Post-transaction value | $54.41 million |
Transaction value based on SEC Form 4 weighted average purchase price ($8.81); post-transaction value based on Sept. 10, 2026 market close ($8.84).
Key questions
- What were the specific execution details of the purchase?
The CEO acquired the shares in multiple open-market transactions on Sept. 10, 2026, with trade prices ranging from $8.73 to $8.84 per share to reach the weighted average of $8.81. - How is the executive's indirect ownership structured?
The executive holds 10,900 shares through an IRA and ~250,000 shares through MOM, LLC, which supplement the direct holding of ~5.9 million shares. - What is the current financial profile of the company?
Alphatec Holdings, Inc. reported trailing twelve-month revenue of $815.1 million and a net loss of $110.0 million as of the latest reporting period. - What is the executive's total equity exposure following this transaction?
Including both direct and indirect holdings, the CEO controls ~6.2 million shares, which represent a market value of $54.41 million as of the Sept. 10, 2026 market close.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-09-10) | $8.84 |
| Market Capitalization | $1.3 billion |
| Revenue (TTM) | $815.1 million |
| Net Income (TTM) | -$110.0 million |
Company Snapshot
- Alphatec Holdings designs and manufactures spinal surgery solutions, including the Alpha InformatiX platform, featuring the SafeOp Neural InformatiX System for intraoperative neuromonitoring, as well as access systems such as the Sigma transforaminal lumbar interbody fusion system.
- The company generates revenue through the sale of surgical instrumentation, implants, and neuromonitoring technology to hospitals, surgical centers, and spine surgeons performing spinal procedures.
- Alphatec's primary customers are orthopedic and neurosurgeons, hospital systems, and ambulatory surgical centers that perform spinal fusion and decompression procedures.
Alphatec Holdings is a specialized medical device manufacturer with approximately $815.1 million in trailing twelve-month (TTM) revenue, focused on advancing the surgical management of spinal conditions through innovative instrumentation and neuromonitoring solutions. The company operates with 913 employees and maintains a market capitalization of $1.3 billion, serving a substantial addressable market in the spine surgery sector. Alphatec's competitive positioning centers on its proprietary intraoperative neuromonitoring technology and integrated surgical access systems designed to enhance procedural safety and clinical outcomes.
What this transaction means for investors
Patrick has been Chairman and CEO of Alphatec Holdings since October 2017. After nearly a decade at the helm, he must know the business inside and out. That he has just added $1 million of shares bought from his own wallet is a bullish sign.
Why? Consider the dynamics of insider buying and selling. There are many reasons an insider may sell shares, some of which have no bearing on their belief in the stock's direction, such as having to pay a large personal expense or diversifying their holdings.
Then consider that there is only one reason an insider buys shares: they believe the stock price will rise.
By that rule of thumb alone, Patrick's purchase of Alphatec stock is bullish. That signal is further bolstered by studies showing that, more often than not, an insider purchase predicts a higher share price 30 days later.
Business is good, too. In its second quarter of the current fiscal year, it did $214 million in sales, up 15%, with surgical revenue up 17%, cases up about 20%, and surgeons using its tools up about 24%.
"Those are the leading indicators that affirm that this is both a utilization story and an adoption story. We're adding surgeons. They are doing more with us. The business is working, and we are scaling," Patrick told investors during its earnings call in early August.
That he is buying shares is a demonstration that he believes what he has been telling Wall Street. It's a sign for investors to invest more deeply if Alphatec is right for their portfolio.
Should you buy stock in Alphatec right now?
Before you buy stock in Alphatec, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Alphatec wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $379,123!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,396,103!*
Now, it’s worth noting Stock Advisor’s total average return is 933% — a market-crushing outperformance compared to 212% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of September 30, 2026.
Brendan Coffey has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
